Go or no go? Mirati heads to the FDA
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
U-turn confirms that the US cut-price oncology model is dead
EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.
Clinical showdown in immuno-oncology
The latest edition of the PD(L)anner provides key updates and details upcoming global events in immuno-oncology.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Looking beyond Roche’s Tigit bombshell
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
